文献速递细胞病理与分子病理

上清液再利用:实体瘤突变分析的下一代细胞病理学

Salvaging the supernatant: next generation cytopathology for solid tumor mutation profiling.
PubMed 文献 · Mod Pathol · 2018-02-20

研究评估细针穿刺针头冲洗液离心后上清液作为DNA来源用于实体瘤突变分析。25例恶性与10例良性样本中,上清液DNA产量中位数176.4 ng,二代测序检出全部恶性样本的体细胞突变,良性均阴性,与手术标本一致率100%,19例经微滴数字PCR验证。

要点

  • 上清液可提供足量DNA用于二代测序突变检测。
  • 上清液突变与手术标本二代测序结果一致率100%。
  • 微滴数字PCR可在上清液验证热点突变。

核心结论

  • 离心后上清液是细针穿刺样本突变分析的可靠底物。
  • 上清液突变检测与手术标本结果高度一致。

研究设计与样本

  • 研究评估25例恶性与10例良性细针穿刺针头冲洗液离心后上清液。

主要发现

  • 上清液DNA产量均值445 ng,中位数176.4 ng(范围15.1-2958 ng)。
  • 二代测序检出全部25例恶性样本的体细胞突变,良性样本均未检出。
  • 与手术标本二代测序比较显示100%一致。
  • 19例样本中EGFR、KRAS、BRAF、PIK3CA和NRAS突变经微滴数字PCR成功确认。

临床怎么用

  • 可利用弃用上清液进行突变检测,避免为多次分子检测重新活检。
  • 上清液适用于二代测序和微滴数字PCR热点突变检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

With the expanding role of targeted therapy in patients with solid tumors, pathologists face the daunting task of having to maximize limited volume tissue obtained by fine needle aspiration for a variety of molecular tests. While most molecular studies on fine needle aspiration samples have been reported using cellular material, recent studies have shown that a substantial amount of DNA can be retrieved from the supernatant fluid of aspirate needle rinses after cell pelleting for cytospin or cell block preparations. In routine clinical workflow, the supernatant is discarded; however this fluid may provide a complementary source of DNA for tumor mutational profiling. In this study, we evaluated the post-centrifuged supernatant from 25 malignant and 10 benign fine needle aspiration needle rinses. The mean and median DNA yields from the supernatants were 445 ng and 176.4 ng (range, 15.1-2958 ng), respectively. Next generation sequencing using the Ion AmpliSeq Cancer Hotspot Panel v2 detected somatic mutations in all 25 malignant samples. No mutations were detected in any of the benign samples tested. When available, mutations detected in the supernatant fluid were compared to the next generation sequencing analysis performed on a prior or concurrent surgical specimen from the same patient and showed 100% concordance. In a subset of cases (n = 19) mutations in EGFR, KRAS, BRAF, PIK3CA, and NRAS were successfully confirmed by droplet digital PCR, providing an orthogonal platform for mutation analysis. In summary, in this study we show that post centrifuged supernatants from fine needle aspiration needle rinses can provide a robust substrate for expanded mutation profiling by next generation sequencing, as well as hotspot mutation testing by droplet digital PCR. The ability to detect somatic mutations from otherwise discarded supernatant fluids offers the ability to triage and effectively utilize limited volume fine needle aspiration samples when multiple molecular tests are requested, without the need to re-biopsy for additional tissue samples.

来源:Mod Pathol,查看原文。版权归原作者所有。

引用

  1. Roy-Chowdhuri S, Mehrotra M, Bolivar AM, et al. Salvaging the supernatant: next generation cytopathology for solid tumor mutation profiling. Mod Pathol. 2018. PMID: 29463880. doi:10.1038/s41379-018-0006-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。